🔴 Harmony Biosciences is trading 8.41% down in pre-market as Wakix closing arguments leave outcome uncertain

Harmony Biosciences is trading at $33.00, down 8.41%, amid Wakix patent-litigation uncertainty, the clearest recent company-specific overhang.

• Closing arguments in the case against AET Pharma took place earlier this week; no ruling was reported.
• Mizuho saw no clear winner or loser, but said investors viewed the arguments as unfavorable and attributed the prior-session decline to that view.
• October 22 volume was about 2.9 million shares, over three times average. No announcement explained the October 23 pre-market move; third-quarter results are scheduled for November 4.